Download PDF
Semin Liver Dis 2004; 24: 25-31
DOI: 10.1055/s-2004-832925
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Predictors of Response to Therapy for Chronic Hepatitis C

Peter Ferenci1
  • 1Professor of Medicine, Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
Further Information

Publication History

Publication Date:
02 September 2004 (online)

    Permissions and Reprints

Pretreatment prediction of successful interferon-based therapy is less accurate than is prediction based on serum hepatitis C virus (HCV) RNA measurements taken during the first few weeks of therapy. Virological response, defined as loss of detectable virus RNA during the first weeks of treatment, identifies interferon-sensitive virus strains. Studies on viral decline kinetics have shown that interferon-based therapies produce a two-phase reduction in viral RNA levels. Sustained virological response is associated with rapid biphasic viral decline kinetics, resulting in elimination of virus from the blood within 4 to 12 weeks. Rapid viral elimination correlates positively with low incidence of relapse in end-of-treatment virological responders and is, therefore, an important parameter for determining duration or type of therapy. This article reviews the various patient and viral factors that help predict response to various interferon-based therapies, ranging from interferon alone to the new pegylated interferons.

KEYWORDS

Prediction - chronic hepatitis C - viral kinetics - interferon - ribavirin

REFERENCES

  • 1 Davis G L, Lau J Y. Factors predictive of a beneficial response to therapy of hepatitis C.  Hepatology. 1997;  26 122S-127S
    CrossrefPubMedGoogle Scholar
  • 2 National Institutes of Health . National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C.  Hepatology. 1997;  26 2S-10S
    CrossrefPubMedGoogle Scholar
  • 3 McHutchison J, Gordon S, Schiff E et al.. Interferon alfa 2B alone or in combination with ribavirin in naive chronic HCV patients: a US multicenter trial.  Hepatology. 1998;  28 387
    PubMedGoogle Scholar
  • 4 Poynard T, Marcellin P, Lee S S et al.. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.  Lancet. 1998;  352 1426-1432
    CrossrefPubMedGoogle Scholar
  • 5 Lee S S, Heathcote E J, Reddy K R et al.. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD).  J Hepatol. 2002;  37 500-506
    CrossrefPubMedGoogle Scholar
  • 6 Poynard T, McHutchison J, Goodman Z et al.. Is an a la carte combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?.  Hepatology. 2000;  31 211-218
    CrossrefPubMedGoogle Scholar
  • 7 Zeuzem S, Feinman S V, Rasenack J et al.. Peginterferon alfa-2a in patients with chronic hepatitis C.  N Engl J Med. 2000;  343 1666-1672
    CrossrefPubMedGoogle Scholar
  • 8 Fried M W, Shiffman M L, Reddy K R et al.. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.  N Engl J Med. 2002;  347 975-982
    CrossrefPubMedGoogle Scholar
  • 9 Lindsay K L, Trepo C, Heintges T et al.. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.  Hepatology. 2001;  34 395-403
    CrossrefPubMedGoogle Scholar
  • 10 Manns M P, McHutchison J G, Gordon S C et al.. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.  Lancet. 2001;  358 958-965
    CrossrefPubMedGoogle Scholar
  • 11 Izopet J, Payen J L, Alric L et al.. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy.  J Med Virol. 1998;  54 86-91
    CrossrefPubMedGoogle Scholar
  • 12 Rubbia-Brandt L, Giostra E, Mentha G, Quadri R, Negro F. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon.  J Hepatol. 2001;  35 307
    CrossrefPubMedGoogle Scholar
  • 13 Di Bisceglie A M, Bonkovsky H L, Chopra S et al.. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial.  Hepatology. 2000;  32 135-138
    CrossrefPubMedGoogle Scholar
  • 14 Thorburn D, Curry G, Spooner R et al.. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C.  Gut. 2002;  50 248-252
    CrossrefPubMedGoogle Scholar
  • 15 Schalm S W, Fattovich G, Brouwer J T. Therapy of hepatitis C: patients with cirrhosis.  Hepatology. 1997;  26 128S-132S
    CrossrefPubMedGoogle Scholar
  • 16 Kaserer K, Fiedler R, Steindl P et al.. Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C.  Histopathology. 1998;  32 454-461
    CrossrefPubMedGoogle Scholar
  • 17 Everson G T, Jensen D M, Craig J R et al.. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics.  Hepatology. 1999;  30 271-276
    CrossrefPubMedGoogle Scholar
  • 18 Heathcote E J, Shiffman M L, Cooksley W G et al.. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.  N Engl J Med. 2000;  343 1673-1680
    CrossrefPubMedGoogle Scholar
  • 19 Cerny A, Chisari F V. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence.  Hepatology. 1999;  30 595-601
    CrossrefPubMedGoogle Scholar
  • 20 Nelson D R, Marousis C G, Ohno T, Davis G L, Lau J YN. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C.  Hepatology. 1998;  28 225-230
    CrossrefPubMedGoogle Scholar
  • 21 Larrea E, Garcia N, Qian C, Civeira M P, Prieto J. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C.  Hepatology. 1996;  23 210-217
    PubMedGoogle Scholar
  • 22 Cacciola I, Pollicino T, Squadrito G et al.. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.  N Engl J Med. 1999;  341 22-26
    CrossrefPubMedGoogle Scholar
  • 23 Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections.  Clin Infect Dis. 1996;  23 1117-1125
    PubMedGoogle Scholar
  • 24 Soriano V, Sulkowski M, Bergin C et al.. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel.  AIDS. 2002;  16 813-828
    CrossrefPubMedGoogle Scholar
  • 25 Sterling R K, Sulkowski M S. HCV in the setting of HIV or HBV coinfection.  Semin Liver Dis. 2004;  24 61-68
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Hoofnagle J H. Hepatitis C: the clinical spectrum of disease.  Hepatology. 1997;  26 15S-20S
    CrossrefPubMedGoogle Scholar
  • 27 Lawrence S P. Advances in the treatment of hepatitis C.  Adv Intern Med. 2000;  45 65-105
    PubMedGoogle Scholar
  • 28 Doglio A, Laffont C, Caroli-Bosc F X, Rochet P, Lefebvre J C. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant.  J Clin Microbiol. 1999;  37 1567-1569
    PubMedGoogle Scholar
  • 29 Martinot-Peignoux M, Boyer N, Le Breton V et al.. A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C.  Hepatology. 2000;  31 726-729
    CrossrefPubMedGoogle Scholar
  • 30 Hadziyannis S J, Cheinquer H, Morgan T et al.. Peginterferon alfa-2a (40 KD) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose.  J Hepatol. 2002;  36 3
    PubMedGoogle Scholar
  • 31 Farci P, Strazzera R, Alter H J et al.. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome.  Proc Natl Acad Sci USA. 2002;  99 3081-3086
    CrossrefPubMedGoogle Scholar
  • 32 Podevin P, Sabile A, Gajardo R et al.. Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR- independent manner.  Hepatology. 2001;  33 1503-1511
    CrossrefPubMedGoogle Scholar
  • 33 National Institutes of Health . National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: June 10-12, 2002.  Hepatology. 2002;  36(Suppl 1) S3-S20
    CrossrefPubMedGoogle Scholar
  • 34 Bain V G. Effect of HCV viral dynamics on treatment design: lessons learned from HIV.  Am J Gastroenterol. 2001;  96 2818-2828
    CrossrefPubMedGoogle Scholar
  • 35 Zeuzem S, Schmidt J M, Lee J H, Ruster B, Roth W K. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo.  Hepatology. 1996;  23 366-371
    PubMedGoogle Scholar
  • 36 Neumann A U, Lam N P, Dahari H et al.. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.  Science. 1998;  282 103-107
    CrossrefPubMedGoogle Scholar
  • 37 Zeuzem S, Schmidt J M, Lee J H et al.. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.  Hepatology. 1998;  28 245-252
    CrossrefPubMedGoogle Scholar
  • 38 Herrmann E, Neumann A U, Schmidt J M, Zeuzem S. Hepatitis C virus kinetics.  Antivir Ther. 2000;  5 85-90
    PubMedGoogle Scholar
  • 39 Neumann A U, Lam N P, Dahari H et al.. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus.  J Infect Dis. 2000;  182 28-35
    CrossrefPubMedGoogle Scholar
  • 40 Zeuzem S, Herrmann E, Lee J H et al.. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a.  Gastroenterology. 2001;  120 1438-1447
    PubMedGoogle Scholar
  • 41 Boyer N, Marcellin P. Natural history of hepatitis C and the impact of anti-viral therapy.  Forum. 2000;  10 4-18
    PubMedGoogle Scholar
  • 42 Bergmann C C, Layden J E, Levy-Drummer R S et al.. Clinical implications of a new tri-phasic model for hepatitis C viral kinetics during IFN-a therapy.  Hepatology. 2001;  34 345A
    PubMedGoogle Scholar
  • 43 Bekkering F C, Brouwer J T, Leroux-Roels G et al.. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy.  J Hepatol. 1998;  28 960-964
    CrossrefPubMedGoogle Scholar
  • 44 Zeuzem S, Lee J H, Franke A et al.. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa.  Hepatology. 1998;  27 1149-1156
    CrossrefPubMedGoogle Scholar
  • 45 Bekkering F C, Brouwer J T, Schalm S W, Elewaut A. Hepatitis C: viral kinetics.  Hepatology. 1997;  26 1691-1693
    PubMedGoogle Scholar
  • 46 Jessner W, Gschwantler M, Steindl-Munda P et al.. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study.  Lancet. 2001;  358 1241-1242
    CrossrefPubMedGoogle Scholar
  • 47 Ferenci P, Shiffman M, Fried M et al.. Early prediction of response to 40 kDa peginterferon alfa-2a (PEGASYS®) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC).  Hepatology. 2001;  34 351A
    CrossrefPubMedGoogle Scholar
  • 48 Jessner W, Stauber R, Hackl F et al.. Early viral kinetics on treatment with pegylated interferon α-2a in chronic hepatitis C genotype 1 infection.  J Viral Hepat. 2003;  10 37-42
    CrossrefPubMedGoogle Scholar
  • 49 Davis G L. Monitoring of viral levels during therapy of hepatitis C.  Hepatology. 2002;  36 S145-S151
    CrossrefPubMedGoogle Scholar
  • 50 Neumann A U, Zeuzem S, Brunda M J. Rapid viral response to treatment with pegylated (40KDA) interferon alfa-2a (Pegasys TM) is strongly predictive of a sustained virologic response in patients with chronic hepatitis C.  Hepatology. 2000;  32 318A
    PubMedGoogle Scholar
  • 51 Peg-Intron package insert Kenilworth, NJ; Schering Corp 2001
  • 52 Herxenberg L A, Moore W A, De Rosa S C. Estimation of missing values.  Lancet. 1999;  354 686
    PubMedGoogle Scholar
  • 53 McHutchison J G, Manns M, Patel K et al.. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.  Gastroenterology. 2002;  123 1061-1069
    CrossrefPubMedGoogle Scholar
  • 54 Civeira M P, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C.  J Hepatol. 1999;  31 237-243
    CrossrefPubMedGoogle Scholar
  • 55 McHutchison J G, Shad J A, Gordon S C et al.. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy.  J Viral Hepat. 2001;  8 414-420
    CrossrefPubMedGoogle Scholar

Peter FerenciM.D. 

Professor of Medicine, Klinische Abteilung Gastroenterologie und Hepatologie, Universitätsklinik für Innere Medizin IV

Währinger Gürtel 18-20

A-1090 Wien, Austria

Email: peter.ferenci@akh-wien.ac.at